BTIG analyst Julian Harrison has assigned their bullish stance on LQDA stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Buy rating due to a combination of factors tied to Yutrepia’s exceptional commercial ramp and the company’s strengthening financial profile. He highlights that Yutrepia is tracking as one of the strongest drug launches in recent years, with rapid quarter‑over‑quarter sales growth, expanding prescriber adoption, and management’s new multiyear revenue outlook that now targets over $1 billion in 2027, supported by broad and deep patient utilization trends.
He also points to Liquidia’s advancing pipeline, particularly the planned Phase 3 Re-Spire study of L606 in PH-ILD, which is designed with robust endpoints and could support future approvals in multiple pulmonary hypertension indications. In Harrison’s view, the company’s healthy cash position, limited perceived competitive risk from other therapies, and a favorable risk‑reward profile ahead of key legal and regulatory milestones justify a higher price target and support his Buy recommendation.
According to TipRanks, Harrison is a 5-star analyst with an average return of 38.1% and a 54.47% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Apogee Therapeutics, Nektar Therapeutics, and MoonLake Immunotherapeutics.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $54.00 price target.